Source Genomics offers Illumina TruSight Oncology 500 (TSO500) next-generation sequencing as a service for comprehensive genomic profiling of tumour samples.
Using the TSO500 assay we have the capability to run a single comprehensive NGS assay, greatly increasing the chances of identifying a positive biomarker.
Outsourcing your genomic profiling with Source Genomics provides access to our highly experienced scientists and state-of the art ISO accredited genomics facilities, therefore guaranteeing consistently high-quality results and unrivalled turnaround times across every project.
Contact us to discuss your next project.
The benefits of partnering with Source Genomics for your next TSO500 project:
Unrivaled turnaround times.
Consistent high-quality results across every project.
Scientists are qualified and experienced with the TSO500 assay.
Europe’s leading provider of commercial sequencing.
Sequencing takes place in-house at ISO accredited laboratories, no outsourcing to additional or third-party sites.
Free consultation and support throughout each project.
TruSight Oncology 500 enables researchers to characterize tumours and identify the next generation of clinical biomarkers. The assay analyses 523 cancer-relevant genes from both DNA and RNA in one integrated workflow. It assesses multiple variant types in a single assay including small nucleotide variants (SNVs), indels, splice variants, fusions and emerging immunotherapy biomarkers including microsatellite instability (MSI) and tumour mutational burden (TMB).
The TruSight Oncology 500 Assay offers many benefits including:
Comprehensive coverage of pan-cancer content, aligned with key guidelines spanning 523 cancer-relevant genes for assessment of all DNA and RNA variant types, and MSI and TMB. Moving to a single comprehensive NGS assay from individual biomarker assays increases the chances of finding a positive biomarker.
Enrichment chemistry including UMIs coupled with an informatics pipeline for high accuracy in variant detection.